MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 05-16-2026
Calliditas Therapeutics AB (publ) Revenue 2011-2026 | CALT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Calliditas Therapeutics AB (publ)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 874 K | 185 M | - | - | - | - | - | - | - | - |
All numbers in SEK currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 185 M | 874 K | 92.9 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 5.72 | -2.39 % | $ 85 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 2.79 | 0.72 % | $ 1.07 B | Canada |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
272 M | $ 33.46 | 1.09 % | $ 1.23 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 2.48 | 4.2 % | $ 314 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Canopy Growth Corporation
CGC
|
269 M | $ 1.02 | - | $ 110 M | Canada |
 |
Pacira BioSciences
PCRX
|
542 M | $ 23.21 | 1.53 % | $ 1.07 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
14.3 M | $ 1.11 | 1.83 % | $ 1.38 M | USA |
 |
Solid Biosciences
SLDB
|
8.09 M | $ 6.57 | 2.5 % | $ 575 M | USA |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.38 | -0.88 % | $ 185 M | Canada |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.08 | 0.93 % | $ 103 M | Canada |
 |
Tilray
TLRY
|
627 M | $ 5.17 | 2.78 % | $ 3.19 B | Canada |
 |
Evolus
EOLS
|
297 M | $ 6.7 | 0.3 % | $ 432 M | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.46 | 0.69 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
743 M | $ 7.95 | -0.63 % | $ 425 M | USA |
 |
Veru
VERU
|
16.9 M | $ 3.1 | 3.33 % | $ 45.4 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
19.2 M | $ 0.72 | -0.69 % | $ 2.9 M | USA |
 |
Assertio Holdings
ASRT
|
119 M | $ 23.46 | 0.13 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 5.17 | 1.17 % | $ 1.92 B | Canada |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 6.27 | 9.62 % | $ 248 M | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 4.36 | -2.02 % | $ 218 M | USA |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
14.3 B | $ 16.2 | 1.69 % | $ 18.9 B | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
86 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 0.69 | 3.81 % | $ 24.8 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.72 | 0.75 % | $ 3.09 M |  China |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 1.88 | - | $ 21.7 M | USA |